Celgene plans to submit Abraxane, or paclitaxel, within the next five months for FDA approval as a treatment for pancreatic cancer after obtaining promising results from a Phase III study. Patients with advanced pancreatic cancer who took Abraxane, in combination with gemcitabine, had median overall survival of 8.5 months versus 6.7 months for those given gemcitabine alone. Abraxane is already cleared for lung and breast cancer.

Full Story:

Related Summaries